Search
Search Results
-
CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison
BackgroundCAR NK cells as vehicles for engineered “off-the-shelf” cellular cancer immunotherapy have attracted significant interest. Nonetheless, a...
-
Forks in the road for CAR T and CAR NK cell cancer therapies
The advent of chimeric antigen receptor (CAR) T cell therapy has resulted in unprecedented long-term clearance of relapse/refractory hematological...
-
Breakthrough of solid tumor treatment: CAR-NK immunotherapy
As the latest and most anticipated method of tumor immunotherapy, CAR-NK therapy has received increasing attention in recent years, and its safety...
-
In vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy
Natural killer (NK) cells have clinical potential against cancer; however, multiple limitations hinder the success of NK cell therapy. Here, we...
-
Outsmarting trogocytosis to boost CAR NK/T cell therapy
Chimeric antigen receptor (CAR) NK and T cell therapy are promising immunotherapeutic approaches for the treatment of cancer. However, the efficacy...
-
Single VHH-directed BCMA CAR-NK cells for multiple myeloma
Natural killer (NK) cells are promising alternatives for the production of “off-the-shelf” CAR products, posing a lower risk of cytokine release...
-
A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases
Chimeric Antigen Receptor (CAR) based therapies are becoming increasingly important in treating patients. CAR-T cells have been shown to be highly...
-
High yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy
Chimeric antigen receptors (CARs) offer a promising new approach for targeting B cell malignancies through the immune system. Despite the proven...
-
Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions
Cancer immunotherapy harnesses the body’s immune system to combat malignancies, building upon an understanding of tumor immunosurveillance and immune...
-
Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer
BackgroundAdoptive cell therapy has achieved great success in treating hematological malignancies. However, the production of chimeric antigen...
-
Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia
Acute myeloid leukemia (AML) still constitutes a dreadful disease with limited therapeutic options. Chimeric antigen receptor (CAR)-modified T cells...
-
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made tremendous progress with five CAR T therapies approved by the US...
-
CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
Chimeric antigen receptor (CAR) T cell therapy is effective in treating B cell malignancies, but factors influencing the persistence of functional CAR
-
Imaging CAR-NK cells targeted to HER2 ovarian cancer with human sodium-iodide symporter-based positron emission tomography
Chimeric antigen receptor (CAR) cell therapies utilize CARs to redirect immune cells towards cancer cells expressing specific antigens like human...
-
Understanding the Interplay of CAR-NK Cells and Triple-Negative Breast Cancer: Insights from Computational Modeling
Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells have recently emerged as a promising and safe alternative to CAR-T cells for...
-
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
Chimeric antigen receptor (CAR)-NK cell therapy has the advantages of a low incidence of side effects and a low cost. However, the clinical outcomes...
-
CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma
BackgroundChimeric antigen receptor NK (CAR-NK) cell therapy is one of the most promising immunotherapies. Although it has shown a significant...
-
A Nonviral piggyBac Transposon-Mediated Method to Generate Large-Scale CAR-NK Cells from Human Peripheral Blood Primary NK Cells
With the inherent antitumor function and unique “off-the-shelf” potential, genetically engineered human natural killer (NK) cells with chimeric...
-
Biomarkers as targets for CAR-T/NK cell therapy in AML
The most common kind of acute leukemia in adults is acute myeloid leukemia (AML), which is often treated with induction chemotherapy regimens...
-
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape
Trogocytosis is an active process that transfers surface material from targeted to effector cells. Using multiple in vivo tumor models and clinical...
